US 11,993,606 B2
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Mohamed-Eslam F. Mohamed, Gurnee, IL (US); Ahmed A. Othman, Libertyville, IL (US); Aileen L. Pangan, La Grange, IL (US); In-Ho Song, Vernon Hills, IL (US); Ben Klünder, Ludwigshafen (DE); Jeffrey W. Voss, Hudson, MA (US); Robert J. Padley, Highland Park, IL (US); and Heidi S. Camp, Winnetka, IL (US)
Assigned to AbbVie Inc., North Chicago, IL (US)
Filed by AbbVie Inc., North Chicago, IL (US)
Filed on Aug. 21, 2023, as Appl. No. 18/453,085.
Application 18/453,085 is a division of application No. 18/176,850, filed on Mar. 1, 2023, granted, now 11,773,106.
Application 18/176,850 is a continuation of application No. 17/979,703, filed on Nov. 2, 2022, abandoned.
Application 17/979,703 is a continuation of application No. 17/717,486, filed on Apr. 11, 2022, granted, now 11,524,964, issued on Dec. 13, 2022.
Application 17/717,486 is a continuation in part of application No. 17/184,194, filed on Feb. 24, 2021, abandoned.
Application 17/184,194 is a continuation in part of application No. 17/039,470, filed on Sep. 30, 2020, abandoned.
Application 17/184,194 is a continuation of application No. 16/656,237, filed on Oct. 17, 2019, abandoned.
Application 16/656,237 is a continuation of application No. 15/891,012, filed on Feb. 7, 2018, abandoned.
Application 15/891,012 is a continuation of application No. 15/295,561, filed on Oct. 17, 2016, abandoned.
Claims priority of provisional application 63/253,109, filed on Oct. 6, 2021.
Claims priority of provisional application 63/032,042, filed on May 29, 2020.
Claims priority of provisional application 62/968,849, filed on Jan. 31, 2020.
Claims priority of provisional application 62/927,548, filed on Oct. 29, 2019.
Claims priority of provisional application 62/908,163, filed on Sep. 30, 2019.
Claims priority of provisional application 62/352,380, filed on Jun. 20, 2016.
Claims priority of provisional application 62/301,537, filed on Feb. 29, 2016.
Claims priority of provisional application 62/267,672, filed on Dec. 15, 2015.
Claims priority of provisional application 62/242,797, filed on Oct. 16, 2015.
Prior Publication US 2023/0399333 A1, Dec. 14, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4985 (2006.01); A61K 9/00 (2006.01); A61K 47/12 (2006.01); A61K 47/38 (2006.01); C07D 487/14 (2006.01)
CPC C07D 487/14 (2013.01) [A61K 9/0053 (2013.01); A61K 31/4985 (2013.01); A61K 47/12 (2013.01); A61K 47/38 (2013.01); C07B 2200/13 (2013.01)] 13 Claims
 
1. A method of treating a human patient having active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation, comprising orally administering once daily to the patient a tablet comprising a therapeutically effective amount of (3 S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide (Compound 1), wherein the therapeutically effective amount is 15 mg.